Contrast media and bronchospasm: A study with iopamido

Dawson, Peter; Pitfield, Jean; Britton, J.

doi:10.1016/s0009-9260(83)80313-4

Cited by 52 publications

(7 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The severe reactions result in respiratory arrest and cardiac abnormality leading to convulsions and failure. 36,46,52,56,58,62,64,66,68,70,89,115,118 These are anaphylactoid type of reactions and are mediated by certain autocoids that are generated in large amounts during the contrast media administra tion. 94,97,99,167 These reactions are compounded by the fact that contrast agents may also produce direct effects on various cellular and/or humoral systems.…”

Section: Fig 23 Reactions To Contrast Media and Their Manage Mentmentioning

confidence: 99%

Molecular Markers of Contrast Media-Induced Adverse Reactions

Fareed¹,

Moncada²,

Messmore³

et al. 1984

Semin Thromb Hemost

View full text Add to dashboard Cite

Currently used routine laboratory screening methods are not reliable in the prediction of contrast media-related adverse reactions. Cost-effective laboratory methods for various molecular markers of pathophysiologic activation have now become available. In vitro activation tests in high-risk patients may prove to be useful in the prediction of contrast-induced activation of various adverse reactions. If prior clinical evaluation of a patient suggests an ongoing pathologic process, profiling of the following molecular markers may prove to be useful and helpful in avoiding contrast-induced adverse reactions: Fibrinopeptide A, platelet factor 4, thromboxane B2, 5-HETE, physiologic inhibitors of proteases, B beta 15-42 related peptides, bradykinin/kininogen, and anaphylactozins. In patients suspected of reacting to contrast agents, a small dose of 1 to 5 ml can be injected as a bolus and molecular marker profiling on blood drawn after the infusion may prove to be useful screening tests. Additional clinical studies are needed to prove this. However, this screening test should be performed with extreme caution, since some of the patients are known to react to as little as 1 ml dose. The safety of newly developed nonionic contrast agents can be readily assessed by profiling various molecular markers of adverse reactions, which provide a more reliable and quantitative assessment of contrast-induced adverse reactions. Based on molecular marker profiling, various prophylactic agents can be given to high-risk patients to avoid contrast-induced adverse reactions.

show abstract

Section: Fig 23 Reactions To Contrast Media and Their Manage Mentmentioning

confidence: 99%

Molecular Markers of Contrast Media-Induced Adverse Reactions

Fareed¹,

Moncada²,

Messmore³

et al. 1984

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…No significant changes in the mean FEV 1 /FVC ratios were detected in our study. These results revealed a predominant restrictive pattern in pulmonary functions in contrast to the study by Dawson et al [13]. In that study sodium iothalamate and iopamidol were compared regarding the adverse effects on respiratory funcTime (According to coronary angiography stages) tions of the patients who underwent urography.…”

Section: Discussionmentioning

confidence: 75%

“…The reductions in FEV 1 are possibly due to the asymptomatic bronchospasm. The underlying mechanism may involve a direct effect on the bronchi, the release of the bronchospastic mediators from mast cells and platelets, cholinesterase inhibition, vagal reflex and complement activation [5].…”

Section: Introductionmentioning

confidence: 99%

Effects of iohexol on ventilatory functions in patients undergoing diagnostic coronary angiography

Özhan

Akdemir

Balbay

et al. 2004

Int J Cardiovasc Imaging

View full text Add to dashboard Cite

show abstract

“…Although symptomatic bronchospasm is very rare (occurring in 0.001% of all examined individuals), sub-clinical bronchospasm as assessed by a fall in FEV 1 values is common, particularly in patients with a history of allergy and/or asthma [21][22][23][24] . In fact, it has been well recognized that a broncho-obstructive event may be induced either in the context of systemic (anaphylactic/anaphylactoid) reactions or as a single clinical manifestation following the use of GA or RCM 12 .…”

Section: Introductionmentioning

confidence: 99%